Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo
ACS medicinal chemistry letters(2022)
摘要
Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.
更多查看译文
关键词
cyanine,MHI-148,PARP inhibitor,rucaparib,glioblastoma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要